AZD2171
Term · Oncology and biomedicine · MLC-T-ONC-000880
A substance being studied in the treatment of some types of cancer. AZD2171 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called cediranib maleate and Recentin.
| Identifier | MLC-T-ONC-000880 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | cediranib maleate; Recentin |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-000880",
"term": "AZD2171",
"field": "Oncology and biomedicine",
"definition": "A substance being studied in the treatment of some types of cancer. AZD2171 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called cediranib maleate and Recentin.",
"expansions": [
"cediranib maleate",
"Recentin"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/azd2171/"
}
Record 3,215 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.